Demographic and disease characteristics from visit immediately before methotrexate reinitiation in patients who reinitiated methotrexate within 4 weeks of entry into the OLE and those who reinitiated at a later time point
| Characteristic, mean±SD | MTX use before week 4 n=26 | MTX use after week 4 n=30 |
| Age, years* | 50.0±15.8 | 52.2±16.4 |
| RA duration, years* | 0.5±0.6 | 0.9±0.9 |
| DAS28(CRP) | 1.9±0.5 | 3.0±1.4† |
| CRP (mg/dL) | 0.4±0.2 | 1.1±1.2 |
| SJC (0–66 joints) | 1.4±3.0 | 3.8±5.7 |
| TJC (0–68 joints) | 1.6±3.7 | 5.9±7.5 |
| HAQ-DI (range, 0–3) | 0.2±0.2 | 0.5±0.7† |
| PGA (0–100 mm VAS) | 4.9±8.4 | 19.3±17.1 |
| PtGA (0–100 mm VAS) | 6.6±8.4 | 19.8±26.0† |
| CDAI (0–76) | 13.0±13.5 | 17.6±16.7 |
*Baseline values.
†n=29.
CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28(CRP), 28-joint Disease Activity Score using C reactive protein; HAQ-DI, Disability Index of the Health Assessment Questionnaire; MTX, methotrexate; OLE, open-label extension; PGA, Physician Global Assessment; PtGA, Patient Global Assessment; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, Visual Analog Scale.